featured
2021 Top Story in Breast Cancer: Updated Results of monarchE and the Approval of Abemaciclib in the Adjuvant Setting
Written by
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
- Johnston SRD, Harbeck N, Hegg R, et al. Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+HER2- node-positive high-risk early breast cancer (monarchE). J Clin Oncol. 2020;38(34):3987-3998.
- Harbeck N, Rastogi P, Martin M, et al. Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: Updated efficacy and Ki-67 analysis for the monarchE study. Ann Oncol. 2021:32(12):1571-1581.
- US Food and Drug Administration. FDA approves abemaciclib with endocrine therapy for early breast cancer. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-abemaciclib-endocrine-therapy-early-breast-cancer. October 12, 2021. Accessed December 3, 2021.
Disclosure statements are available on the authors' profiles: